

Ad hoc announcement pursuant to Art. 53 LR
2024 half-year report – media release

Straumann Group reports strong growth in the second quarter and updates outlook due to selling DrSmile

- Half-year revenue reached CHF 1.3 billion¹, growing 16.1%¹ organically, achieving CHF 654.9 million¹ or 14.8%¹ in the second quarter
- Core² EBIT margin at 27.8%¹ including currency headwinds, in the first half year
- DrSmile to be sold to Impress Group; Straumann Group to keep minority of 20% in the combined entity
- Transitions in the Executive Management Board
- Updated outlook 2024 for continuing operations: organic revenue growth in the low double-digit percentage range and profitability in the 27-28% range at constant 2023 currency rates

	H1 2024		H1 2023 ¹	
	IFRS	CORE ²	IFRS	CORE ²
Revenue	1273.3	1273.3	1143.9	1143.9
Change CHF		11.3%		2.1%
Change (CER ³)		17.6%		7.9%
Change organic		16.1%		7.8%
Gross profit	918.4	922.8	861.1	861.2
Margin	72.1%	72.5%	75.3%	75.3%
Margin change CHF		(280bps)		(100bps)
Margin change (CER ³)		(180bps)		(10bps)
EBITDA	406.5	415.9	377.4	387.2
Margin	31.9%	32.7%	33.0%	33.9%
Margin change CHF		(120bps)		(190bps)
Margin change (CER ³)		50bps		(20bps)
EBIT	336.1	354.4	311.9	331.6
Margin	26.4%	27.8%	27.3%	29.0%
Margin change CHF		(120bps)		(220bps)
Margin change (CER ³)		70bps		(50bps)
Net result	268.2	282.1	225.3	254.0
Margin	21.1%	22.2%	19.7%	22.2%
Margin change CHF		0bps		(320bps)
Basic EPS (in CHF)	1.67	1.76	1.41	1.59
Free cash flow	145.3		142.7	
Margin	11.4%		12.5%	
Headcount (end of June)	11 145		9 956	

¹ Figures refer to continuing operations, following the agreement signed on August 13, 2024, to sell the Group's DrSmile business to Impress Group. Details on the discontinued operations can be found on page 25f.

² The 'core' figures in this document exclude M&A effects from purchase-price allocation (PPA) amortization and related changes of contingent considerations, impairments, restructuring expenses, legal cases, consolidation result of former associates, and other non-recurring incidents. Details and a reconciliation of the reported and core income statement are provided on pages 12ff.

³ Constant exchange rate (CER) equals prior-year figures at 2024 currency exchange rates.

Basel, August 14, 2024: Straumann Group reports revenue⁴ of CHF 1.3 billion in the first six months of 2024, representing an organic revenue growth of 16.1%. Overall, the specific patient flow dynamic per region remained the same as in the first quarter, which resulted in achieving double-digit organic revenue growth of 14.8% in the second quarter, against a strong comparison quarter, or a revenue growth of 12.4% in Swiss francs. The Asia Pacific region was growing the fastest, despite a gradually normalizing baseline in China, and LATAM showed a solid double-digit growth despite the heavy floods in Brazil. The NAM regional performance sequentially improved, with the same patient flow dynamic as in the first quarter 2024. The EMEA region performed strongly with 12.4% organic revenue growth, driven by both implantology and ClearCorrect, the Group's business-to-business orthodontic brand.

Globally, ClearCorrect continued to show solid double-digit growth performance in the second quarter. The implantology business being the main revenue contributor drove growth in all areas in the premium and challenger segment which was attributable to their continued geographical expansion and significant investments in education. Revenue from intraoral scanners, which are the entry point to the digital workflow, progressed well, while the Group continued to build the infrastructure of its digital platform Straumann AXS, endorsing the strategy to offer a fully digital cloud-based clinical workflow.

On 13 August 2024, the Group signed a definitive agreement to sell its DrSmile business to [Impress Group](#). With this, Impress Group aims to build a leadership position in the direct-to-consumer clear aligner space in Europe.

Guillaume Daniellot, Chief Executive Officer, commented: "We are very pleased with the half-year results. Our double-digit revenue growth reflects the team's continued strong execution which led to winning new customers and gaining market share. What stood out in the second quarter were our intensified education efforts in all business areas, with the ITI World Symposium in Singapore being clearly the highlight. On top of these efforts, we launched new customer-centric solutions such as iEXCEL and UN!Q. On the consumer side, selling DrSmile to Impress Group will give this company the necessary scale and patient journey expertise to further strengthen patient care to succeed in the European direct-to-consumer clear aligner market. Due to this new situation, we restated the figures and updated our outlook for 2024."

In the second quarter, revenue in Swiss francs continued to be impacted by negative currency developments, mainly related to the Euro, the Chinese Renminbi and various emerging currencies. While the Group continued to invest significantly in capacity expansion, education and digital transformation, core EBIT margin reached 27.8% including currency headwinds.

⁴ Figures refer to continuing operations, following the agreement signed on August 13, 2024, to sell the Group's DrSmile business to Impress Group. Details on the discontinued operations can be found on page 25f.

STRATEGIC PROGRESS IN THE SECOND QUARTER

DrSmile to be sold to Impress Group; Straumann Group to keep minority shareholdings of 20%

On August 13, 2024, the Group signed a definitive agreement to sell its DrSmile business to Impress Group and in return will receive a minority shareholding of 20% (on a fully diluted basis) in the company. The transaction is expected to close in due course.

Founded in 2019 and headquartered in Barcelona, Spain, Impress Group is a leading provider of clear aligners in Europe and operates a network of clinics in countries such as Spain, the UK, Italy and Portugal. With the acquisition of DrSmile, Impress Group is well positioned to compete in this market by combining quality clinical treatment with consumer marketing expertise at scale.

The Impress Group covers the end-to-end patient journey, from the initial consultation to the clinical result, which greatly enhances the patient experience. In addition, Impress Group will benefit from a larger geographical footprint by adding Germany, France, the Netherlands and Sweden. The Impress Group commits to ensure the continuing support of all DrSmile patients currently undergoing treatment while Straumann Group will continue to be a major supplier of clear aligners for Impress Group.

Education as a driver for implantology – ITI World Symposium in Singapore

In the second quarter, educational events and activities helped attract new customers and expand market share. One highlight was the ITI (International Team for Implantology) World Symposium in Singapore held in May. More than 5 700 dental professionals attended this event, which was the largest ITI congress ever. The event was mainly supported by Straumann Group, presenting its latest innovations and organizing many scientific and educational activities, that were highly appreciated by practitioners from more than 100 countries. In parallel, challenger brands like Neodent intensified their education activities across the regions, namely in Brazil, Malaysia and India.

Custom implant prosthetics – UN!Q launched in North America

As one outcome of its significant investment in digital transformation, Straumann Group has launched a truly customer-centric solution in North America: Straumann UN!Q. It is a digital on-demand service, that allows dental laboratories to outsource the planning, design and manufacturing of their patient-specific implant prosthetics. With UN!Q, customers benefit from an extensive portfolio and an on-demand workflow that is tailored to their needs. In line with Straumann Group's aspiration to become a digitally-powered oral care company, the entire workflow is based on the Group's digital platform Straumann AXS which is transforming the customer experience for all dental laboratory partners.

Straumann SIRIOS intraoral scanner presented at ITI World Symposium

In May, the intraoral scanner (IOS) Straumann SIRIOS was presented at the ITI World Symposium in Singapore. Thanks to its specific technology, the wireless IOS delivers speed and accuracy to customers and complements the Group's IOS offering with a solution in the mid- to entry-level segment.

While Sirios is an open-system solution, its full integration in Straumann AXS, the Group's digital platform, supports customers in gaining efficiency in their clinical workflow.

Full acquisition of mininavident – Straumann Falcon launched successfully

In July, Straumann Group completed the acquisition of mininavident, a company based in Liestal, Switzerland, that focuses on developing a miniaturized dynamic navigation system. Its solution, Straumann Falcon, provides guidance during dental-implant surgery by combining free-hand technique with 3D visualization, supporting the clinician in the decisive step of drilling and inserting an implant. Falcon was well perceived at its presentation at the ITI symposium in Singapore. Straumann Group announced in October 2021 that it had acquired 39% of mininavident. The completion of the acquisition supports the Group's aspiration to offer a differentiated and efficient dynamic navigation system and simplifies development cooperation and market access.

ClearCorrect further enhanced its doctor-facing platforms

Next to intensified education activities, ClearCorrect continued to strengthen its presence in existing markets and further enhanced its doctor-facing platforms for a more efficient practice management. In spring, the new version of the ClearCorrect app, Sync 2.0, was launched globally. It offers clinicians an expanded range of features to easily start, review and manage cases and allows to enter ClearPilot directly. This recently launched software was well received by clinicians, thanks to its advanced editing tools.

Executive Management Board Announcements

Sara Dalmasso will join Straumann Group on August 19, 2024, as Head of the Dental Service Organization (DSO). Sara has held several leadership positions at Omnicell and GE Healthcare, where she has demonstrated her ability to grow franchises and lead diverse teams toward sustainable growth and margin expansion.

After five years at the Straumann Group as Chief People Officer and an impressive career across different industries, Alastair Robertson has decided to retire by the end of 2024. Alastair created significant impact through performing and transforming and made his mark as an exceptional culture leader. Arnoud Michael Middel has succeeded Alastair Robertson in early August as Chief People Officer. Arnoud joined from the Siegfried Group, where he was Chief Human Resources Officer. Over the past 12 years, he supported the company's dynamic growth and transformation from an HR perspective and was instrumental in building and developing a strong global HR practice. Before joining Siegfried, he held senior HR positions at Syngenta, XL Insurance and Baloise Insurance.

In July it was also announced that Matthias Schupp, Head of Latin America region, decided to leave Straumann Group by the end of October 2024 to become CEO of Medartis. In the last 17 years with the Group, Matthias has held various senior leadership roles, before taking the lead of Latin America and the Neodent team in 2014. He has significantly developed the LATAM region and supported the Neodent expansion to become a global challenger brand. The Group expresses its gratitude to Matthias for all his accomplishments over the many years. The recruitment process for his successor is ongoing.

In July, Straumann Group merged its Data & Tech team and the Digital Platform & Technology department. Thomas Friese has been appointed to lead this newly combined team as Chief Technology & Information Officer (CTIO). Thomas, with Straumann Group for two years, has more than 17 years of successful leadership experience in building high-performance teams and digital platforms. Together with his team, he provided, among other achievements, a seamless, high-quality customer experience through integrated and automated digital dental workflows. Christian Ullrich who was the Chief Information Officer at Straumann Group since 2021, left in July to pursue opportunities outside the company. The Group wants to thank him for the many contributions he has made.

More detailed information on the members of the Executive Management Board can be found [here](#).

REGIONAL PERFORMANCES IN THE SECOND QUARTER

Market share gains in the EMEA region continued

The Europe, Middle East, and Africa (EMEA) region reported revenue of CHF 261.3 million in the second quarter, or 12.4% organic growth, with markets such as Italy, Iberia, Germany and Eastern European countries as main revenue contributors. The implant business showed strong double-digit growth, primarily driven by the challenger implantology solutions, namely Neodent and Medentika. In the premium segment, Straumann continued to grow and gain market share, further supported by the promising introduction of iEXCEL in May in France, the first market in EMEA to launch. In the B2B orthodontics business, education efforts and intensified customer acquisition of ClearCorrect led to strong growth.

North America delivered solid growth

The North America region reported revenue of CHF 181.4 million in the second quarter, showing a solid 5.3% organic growth. Patient flow dynamic in the second quarter remained the same as in the first quarter. The implantology business remained the primary growth driver, with Straumann gaining market share in the premium segment and Neodent delivering strong results. iEXCEL, the recently launched premium implant system for immediacy treatments, showed positive momentum in the second quarter. ClearCorrect continued to develop its market penetration by improving its value proposition, mainly with general practitioners and also a small number of orthodontists. The demand for digital solutions also showed positive momentum, thanks to good sales of intraoral scanners and the launch of the custom implant prosthetics service UNIQ.

Asia Pacific region continued to grow strongly

The Asia Pacific region achieved revenue of CHF 154.6 million in the second quarter, a strong 33.8% organic revenue growth against a gradually higher comparison base, as the prior-year quarter was still driven by pent-up demand and the VBP roll-out in China. Implantology remained the main revenue contributor with premium implants and Anthogyr growing in China. The challenger brands Anthogyr and Neodent also grew significantly outside China, namely in Australia, India, Thailand and Vietnam.

Demand for digital solutions like SmileCloud and the AlliedStar intraoral scanners remained encouraging. The orthodontics business had a positive impact on the regional performance.

Latin America continued to deliver double-digit revenue growth despite heavy floods

In the second quarter, Latin America grew 14.9% organically, leading to CHF 57.7 million in revenue. Brazil, as the primary revenue contributor, maintained its double-digit growth despite a flood disaster in the state of Rio Grande do Sul. Straumann Group also gained market share in mature markets like Brazil, driven by continued strong demand for Neodent solutions. The orthodontics business grew at a high double-digit rate and made a significant contribution to the region's performance. Digital solutions, namely the Virtuo Vivo intraoral scanner, also contributed to the region's success. In the second quarter, Straumann Group extended its sales activities to Costa Rica where it started to commercialize the Straumann, Neodent and ClearCorrect portfolio.

REVENUE BY REGION	Q2 2024	Q2 2023⁵	H1 2024	H1 2023⁵
Figures refer to continuing operations ⁵ ; in CHF million				
Europe, Middle East & Africa (EMEA)⁶	261.3	234.1	519.8	486.2
Change CHF	11.6%	2.0%	6.9%	3.7%
Change (CER ⁷)	15.5%	9.3%	13.8%	9.9%
Change organic	12.4%	9.3%	10.8%	9.9%
% of Group total	39.9%	40.2%	40.8%	42.5%
North America (NAM)	181.4	173.2	359.1	355.2
Change CHF	4.7%	0.7%	1.1%	3.8%
Change (CER ⁷)	5.3%	7.0%	4.5%	7.1%
Change organic	5.3%	7.0%	4.5%	7.1%
% of Group total	27.7%	29.7%	28.2%	31.0%
Asia Pacific (APAC)	154.6	122.3	285.4	202.2
Change CHF	26.4%	9.6%	41.2%	(9.7%)
Change (CER ⁷)	34.7%	23.1%	53.6%	(0.3%)
Change organic	33.8%	23.1%	52.3%	(0.8%)
% of Group total	23.6%	21.0%	22.4%	17.7%
Latin America (LATAM)	57.7	53.2	109.0	100.4
Change CHF	8.4%	13.7%	8.6%	16.6%
Change (CER ⁷)	14.9%	20.1%	13.3%	20.1%
Change organic	14.9%	20.1%	13.2%	20.1%
% of Group total	8.8%	9.1%	8.6%	8.8%
Group⁵	654.9	582.8	1 273.3	1 143.9
Change CHF	12.4%	4.1%	11.3%	2.1%
Change (CER ⁷)	16.2%	12.1%	17.6%	7.9%
Change organic	14.8%	12.1%	16.1%	7.8%

⁵ Figures refer to continuing operations, following the agreement signed on August 13, 2024, to sell the Group's DrSmile business to Impress Group. Details on the discontinued operations can be found on page 25f.

⁶ Regional revenue figures including the DrSmile business can be found on page 9.

⁷ Constant exchange rate (CER) equals prior-year figures at 2024 currency exchange rates.

OPERATIONS AND FINANCES⁸

In addition to the results reported under IFRS accounting standards, the Group presents 'core' results to facilitate a like-for-like comparison. In the first six months of 2024, the following pre-tax effects were defined as non-core items:

- Special items, amortization of acquisition-related intangible assets and changes in the fair value of related contingent considerations, amounting to CHF 10 million
- Restructuring costs of CHF 2 million
- Litigation costs of CHF 5 million

A reconciliation table and detailed information are provided on page 14f. of this media release.

Gross profit margin remains at high level

In the first six months of this fiscal year, the Group's strong topline growth led to a core gross profit of CHF 922.8 million, which is a currency-adjusted increase of CHF 119 million. The corresponding margin remained solid at 72.5%, despite an unfavorable mix and a decrease of 100 basis points due to a negative currency effect compared to 2023.

Core EBIT margin of 27.8%

In the first six months, EBIT increased by CHF 23 million, amounting to CHF 354 million, including currency headwinds. The core EBIT margin reached 27.8%, including currency headwinds, 120 basis points lower than in the prior-year period. Currency fluctuations had a negative impact of 190 basis points on the core EBIT margin, which is notably due to the weakened Euro, US Dollar, Chinese Renminbi and emerging currencies.

In the period under review, core distribution expenses rose by CHF 30 million to CHF 238 million, due to higher sales-force expenses and logistics costs. Core administrative expenses increased by CHF 11 million to CHF 337 million.

Core net profit reached CHF 282 million

Core net financial expenses were reduced by CHF 19 million to CHF 6 million. This improvement primarily reflects a stabilizing currency environment compared to last year, notably in emerging markets. Income taxes amounted to CHF 60 million, resulting in an income tax rate of 17.5%. Core net profit reached CHF 282 million, resulting in a margin of 22.2%. Core basic earnings per share increased from CHF 1.59 to CHF 1.76, compared to the prior-year period.

Free cash flow remained stable

Free cash flow generation was CHF 145 million, CHF 3 million higher than in the prior year. Capital expenditure in the first six months remained at high levels with CHF 84 million spent, which reflects the continued investments in production expansion and digital transformation.

The cash position on 30 June 2024 remained strong, at CHF 334 million.

⁸ The numbers stated in the below paragraph reflect continuing operations.

OUTLOOK 2024 UPDATED – (BARRING UNFORESEEN CIRCUMSTANCES)

The Group remains confident that, amidst the ongoing geopolitical and macroeconomic uncertainties, it will continue to gain market share within its estimated global addressable market of more than CHF 19 billion. The Group also believes in its capability to cater to various customer requirements and price points, its geographic diversification and extensive educational initiatives that equip a greater number of clinicians with the expertise to conduct implant and orthodontic treatments. The Group continues to invest in digital transformation, capacity expansion, and, following the sale of DrSmile, will focus even more on go-to-market activities in the orthodontics business-to-business area. Subsequently, the Group updates its outlook for 2024 for continuing operations: to achieve organic revenue growth in the low double-digit percentage range and profitability in the 27-28% range at constant 2023 currency rates.

About Straumann Group

The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Anthogyr, ClearCorrect, Medentika, Neodent, NUVO, Straumann and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CAD/CAM prosthetics, orthodontic aligners, biomaterials and digital solutions for use in tooth correction, replacement and restoration or to prevent tooth loss.

Headquartered in Basel, Switzerland, the Group currently employs more than 11'000 people worldwide. Its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners.

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland

Phone: +41 (0)61 965 11 11

Homepage: www.straumann-group.com

Contacts:

Corporate Communication

Silvia Dobry: +41 (0)61 965 15 62

Frank Keidel: +41 (0)79 530 71 84

E-mail: corporate.communication@straumann.com

Investor Relations

Marcel Kellerhals: +41 (0)61 965 17 51

Derya Güzel: +41 (0)61 965 18 76

E-mail: investor.relations@straumann.com

ANALYSTS' AND MEDIA CONFERENCE CALL

Straumann will present its 2024 second-quarter results to representatives of the financial community and media in a webcast telephone conference call today at 9.30 a.m. Swiss time. The webcast can be accessed via www.straumann-group.com/webcast. A replay of the webcast will be available after the conference.

If you intend to ask a question during the Q&A, we kindly ask you to pre-register for the conference call through this link "[Conference call](#)". We also recommend that you download the presentation file in advance using the direct link in this media release before joining the conference call.

Presentation

The conference presentation slides are attached to this release and available on the Media and Investors pages at www.straumann-group.com.

UPCOMING CORPORATE / INVESTOR EVENTS

2024	Event	Location
15-16 Aug	Jefferies Roadshow	London
4-5 Sep	Goldman Sachs European Medtech Conference	London
10-11 Sep	Kepler Cheuvreux Autumn Conference	Paris
18-19 Sep	Bank of America Global Healthcare Conference	London
29 Oct	Straumann Group Q3 results	

Disclaimer

This press release contains forward-looking statements that reflect the current views, beliefs and expectations of management at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann's control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events, or otherwise. This release constitutes neither an offer to sell nor a solicitation to buy any securities.

ANNEX: REGIONAL REVENUE WITH DRSMILE BUSINESS INCLUDED

REVENUE BY REGION	Q2 2024	Q2 2023	H1 2024	H1 2023
Figures including DrSmile; in CHF million				
Europe, Middle East & Africa (EMEA)	280.9	272.6	564.8	559.1
Change CHF	3.1%	5.2%	1.0%	6.3%
Change (CER ⁹)	6.5%	12.5%	7.0%	12.4%
Change organic	4.1%	8.8%	4.6%	9.0%
% of Group total	41.6%	43.9%	42.8%	45.9%
North America (NAM)	181.4	173.2	359.1	355.2
% of Group total	26.9%	27.9%	27.2%	29.2%
Asia Pacific (APAC)	154.6	122.3	285.4	202.2
% of Group total	22.9%	19.7%	21.6%	16.6%
Latin America (LATAM)	57.7	53.2	109.0	100.4
% of Group total	8.5%	8.6%	8.3%	8.2%
Group	674.5	621.3	1 318.3	1 216.9
Change CHF	8.6%	5.4%	8.3%	3.3%
Change (CER ⁹)	12.2%	13.4%	14.3%	9.1%
Change organic	10.9%	11.7%	12.9%	7.5%

⁹ Constant exchange rate (CER) equals prior-year figures at 2024 currency exchange rates.

Interim selected financial information

OPERATING PERFORMANCE FROM CONTINUING OPERATIONS

(in CHF million; based on IFRS Accounting Standards)	H1, 2024	H1, 2023 ¹
Revenue	1 273.2	1 143.9
Change in %	11.3	2.1
Gross profit	918.4	861.1
Margin in %	72.1	75.3
Operating result before depreciation and amortization (EBITDA)	406.5	377.4
Margin in %	31.9	33.0
Margin change in bps	(110.0)	(270.0)
Operating result (EBIT)	336.1	311.9
Margin in %	26.4	27.3
Margin change in bps	(90.0)	(350.0)
Net profit	268.2	225.3
Margin in %	21.1	19.7
Margin change in bps	140.0	(530.0)
Basic earnings per share (in CHF)	1.67	1.41

¹ Comparative information for 2023 has been adjusted due to the classification of the direct-to-consumer clear aligner business as discontinued operations.

FINANCIAL PERFORMANCE FROM CONTINUING OPERATIONS

(in CHF million; based on IFRS Accounting Standards)	H1, 2024	H1, 2023 ¹
Cash and cash equivalents	333.7	599.0
Net working capital (net of cash)	425.6	339.0
Net cash (net debt)	84.5	101.7
Inventories	406.0	359.1
Days of supplies	196	222
Trade receivables	463.2	396.3
Days of sales outstanding	64	61
Balance sheet total	3 303.5	3 095.9
Return on assets in % (ROA)	12.2	15.2
Equity	1 971.4	1 896.2
Equity ratio in %	59.7	61.2
Return on equity in % (ROE)	20.1	24.9
Capital employed	1 767.9	1 606.8
Return on capital employed in % (ROCE)	30.7	36.5
Cash flows from operating activities from continuing operations	228.6	227.1
in % of revenue	18.0	19.9
Investments from continuing operations	88.8	144.8
in % of revenue	7.0	12.7
thereof capital expenditures	84.0	86.3
thereof business combination related	8.4	31.8
thereof contingent consideration related	6.2	21.7
thereof associates related	(9.8)	4.9
Free cash flow from continuing operations	145.3	142.7
in % of revenue	11.4	12.5
Dividend	135.4	127.4

¹ Comparative information for 2023 has been adjusted due to the classification of the direct-to-consumer clear aligner business as discontinued operations.

Alternative Performance Measures

The financial information in this first-half report includes certain alternative performance measures (APMs), which are not accounting measures defined by IFRS[®] Accounting Standards.

CORE FINANCIAL MEASURES are non-IFRS Accounting Standards measures because they cannot be derived directly from Group consolidated financial statements. Management believes that these measures, when provided in combination with reported results, will provide readers with helpful supplementary information to better understand the financial performance and position of the Group on a comparable basis from period to period. These core financial measures are not a substitute for, or superior to, financial measures prepared in accordance with IFRS Accounting Standards. Core financial measures are adjusted to exclude the following significant items:

- M&A: Special items and amortization of intangible assets resulting from the purchase price allocation (PPA) following acquisitions and changes in the fair value of related contingent considerations.
- Impairments: Impairment write-offs of financial or non-financial assets as a result of unusual or one-time events in legal or economic conditions, change in consumer demands, or damage that impacts the asset.
- Restructuring: One-off costs resulting from major restructuring exercises. The amount disclosed for H1 2024 represents restructuring costs incurred in the EMEA sales region. In H1 2023, restructuring costs were incurred in the LATAM, APAC, and EMEA sales regions.
- Legal cases: Non-recurring and significant legal disputes. The amount disclosed in H1 2024 pertains to expenses related to a litigation. This also includes anticipated costs such as lawyers' and experts' fees. Expenses related to routine legal disputes arising from the Group's ordinary business activities are not adjusted.
- Pension plan: One time settlements, plan amendment gains or losses stemming from pension accounting.
- Consolidation result of former associates: Revaluation gains and losses as a result of obtaining control over former associates.
- Other: Non-recurring, unusual and infrequent incidents that cannot be allocated to any of the preceding categories.

In 2024, changes in the fair value of contingent consideration arising from acquisitions under M&A were adjusted in the core financial measures for the first time, with comparative information restated accordingly.

A reconciliation of IFRS Accounting Standards to core measures is disclosed in the table at the end of this section.

Further, the Group discloses **VARIOUS KEY PERFORMANCE INDICATORS (KPI)**. Unless otherwise stated, the following KPIs are based on IFRS Accounting Standards figures, as disclosed in the consolidated financial statements:

ORGANIC REVENUE GROWTH

Revenue growth excluding the revenue contribution from business combinations (calculated by adding pre-acquisition revenues of the prior period to the existing revenue growth base) and currency effects.

REVENUE GROWTH IN LOCAL CURRENCIES

Revenue growth excluding currency effects. Those effects are calculated using a simulation by reconsolidating the prior period revenues with the current year foreign exchange translation rates.

NET CASH (NET DEBT)

Net debt is an indicator of the Group's ability to meet financial commitments, to pay dividends and to undertake acquisitions. The KPI is calculated by subtracting financial liabilities (excluding lease liabilities) from cash and cash equivalents.

NET WORKING CAPITAL (NET OF CASH)

Working capital is capital invested in the Group's operating activities. It is a driver for cash flow and an indicator of operational efficiency. Net working capital combines the subtotals of current assets and current liabilities, excluding the lines cash and cash equivalents, current financial assets and current financial liabilities.

DAYS OF SUPPLIES (DOS)

The days of supplies indicate the average time in days that the Group takes to turn its inventory. The numerator is the balance sheet position 'inventories' at the balance sheet date, and the denominator is the 'cost of goods sold' of the past three months, multiplied by 90 days.

DAYS OF SALES OUTSTANDING (DSO)

The days of sales outstanding indicate the average number of days the Group takes to collect its receivables. The numerator is the balance sheet position 'trade receivables' at the balance sheet date and the denominator is the 'net revenues' of the past three months, multiplied by 90 days.

RETURN ON ASSETS (ROA)

Return on assets expresses the earning power of the Group's assets. The numerator is the profit for the period of the past twelve months, and the denominator is the average balance sheet total for the same period.

EQUITY RATIO

The equity ratio is calculated by dividing total equity by total assets.

RETURN ON EQUITY (ROE)

Return on equity compares profitability of the Group in relation to the equity invested. The numerator is the profit for the period of the past twelve months, and the denominator is the average equity for the same period.

CAPITAL EMPLOYED

Capital employed equals current assets, property, plant and equipment, right-of-use assets, intangible assets minus cash and cash equivalents and non-interest-bearing liabilities.

RETURN ON CAPITAL EMPLOYED (ROCE)

Return on capital employed expresses the earning power of the Group's invested capital. The numerator is the operating profit (EBIT) of the past twelve months, and the denominator is the average capital employed for the same period.

FREE CASH FLOW

Free cash flow represents the cash-generating capability of the Group to conduct and maintain its operations, to finance dividend payments, to repay debt, and to undertake acquisitions. Free cash flow equals net cash from operating activities less purchase of property, plant and equipment, less purchase of intangible assets, plus net proceeds from property, plant and equipment.

CORE RESULTS RECONCILIATION H1, 2024

H1, 2024 (in CHF 1 000)	IFRS	M&A	Restructuring	Legal cases	CORE
Revenue	1 273 232				1 273 232
Cost of goods sold	(354 833)	2 877	1 492		(350 464)
Gross profit	918 399	2 877	1 492		922 768
Other income	6 379				6 379
Distribution expense	(241 273)	3 199	76		(237 997)
Administrative expense	(347 446)	5 129	580	5 000	(336 738)
Operating profit	336 059	11 204	2 148	5 000	354 412
Finance income	88 604	(10 284)			78 320
Finance expense	(94 102)	9 297			(84 805)
Share of result of associates	(5 858)				(5 858)
Profit before income tax	324 703	10 218	2 148	5 000	342 069
Income tax expense	(56 467)	(2 533)	(446)	(552)	(59 997)
NET PROFIT FROM CONTINUING OPERATIONS	268 236	7 685	1 703	4 448	282 072
Loss from discontinued operations, net of tax	(36 521)	289	5 564		(30 669)
NET PROFIT	231 715	7 974	7 266	4 448	251 403
Attributable to:					
Shareholders of the parent company	230 372	7 927	7 266	4 448	250 013
Non-controlling interests	1 343	47			1 389
Earnings per share (EPS):					
Earnings per share for the period attributable to the owners of the parent:					
Basic (in CHF)	1.45				1.57
Diluted (in CHF)	1.44				1.57
Thereof continuing operations:					
Basic (in CHF)	1.67				1.76
Diluted (in CHF)	1.67				1.76
Operating profit	336 059	11 204	2 148	5 000	354 412
Depreciation & amortization	70 391	(8 391)	(466)		61 534
EBITDA	406 450	2 814	1 682	5 000	415 946

CORE RESULTS RECONCILIATION H1, 2023¹

H1, 2023 (in CHF 1 000)	IFRS	M&A ²	Restructuring	Legal cases	CORE
Revenue	1 143 868				1 143 868
Cost of goods sold	(282 791)	65	63		(282 664)
Gross profit	861 076	65	63		861 203
Other income	3 503				3 503
Distribution expense	(209 864)	2 217			(207 646)
Administrative expense	(342 863)	1 566	15 825		(325 471)
Operating profit	311 853	3 848	15 888		331 589
Finance income	40 384				40 384
Finance expense	(72 518)	6 461			(66 057)
Share of result of associates	(4 629)				(4 629)
Profit before income tax	275 090	10 309	15 888		301 287
Income tax	(49 763)	(1 167)	3 596		(47 334)
NET PROFIT FROM CONTINUING OPERATIONS	225 327	9 143	19 484		253 953
Loss from discontinued operations, net of tax	(19 308)	297			(19 011)
NET PROFIT	206 019	9 440	19 484		234 942
Attributable to:					
Shareholders of the parent company	205 776	9 391	19 484		234 651
Non-controlling interests	243	48			292
Earnings per share (EPS):					
Earnings per share for the period attributable to the owners of the parent:					
Basic (in CHF)	1.29				1.47
Diluted (in CHF)	1.29				1.47
Thereof continuing operations:					
Basic (in CHF)	1.41				1.59
Diluted (in CHF)	1.41				1.59
Operating profit	311 853	3 848	15 888		331 589
Depreciation & amortization	65 501	(3 848)	(6 003)		55 650
EBITDA	377 354		9 885		387 239

¹ Comparative information for 2023 has been adjusted due to the classification of the direct-to-consumer clear aligner business as discontinued operations.

² 'Finance expense' and 'income tax' restated to include changes in the fair value of contingent considerations arising from acquisitions.

Interim condensed consolidated statement of financial position

ASSETS

(in CHF 1 000)	30 Jun 2024	31 Dec 2023
Property, plant and equipment	522 180	503 875
Right-of-use assets	195 665	204 521
Intangible assets	894 854	907 696
Investments in associates	156 811	163 136
Financial assets	44 081	19 488
Other receivables	25 575	26 035
Deferred income tax assets	112 762	106 951
Total non-current assets	1 951 929	1 931 702
Inventories	405 964	366 912
Trade and other receivables	578 998	580 638
Financial assets	10 229	8 974
Income tax receivables	22 672	23 443
Cash and cash equivalents	333 666	410 310
Assets included in a disposal group classified as held for sale	175 072	0
Total current assets	1 526 601	1 390 277
TOTAL ASSETS	3 478 530	3 321 979

EQUITY AND LIABILITIES

(in CHF 1 000)	30 Jun 2024	31 Dec 2023
Share capital	1 595	1 595
Retained earnings and reserves	1 966 534	1 834 584
Total equity attributable to the shareholders of the parent company	1 968 128	1 836 179
Non-controlling interests	3 320	2 427
Total equity	1 971 448	1 838 606
Other liabilities	236 195	213 368
Income tax liabilities	14 642	15 232
Financial liabilities	423 006	420 196
Provisions	30 368	27 253
Retirement benefit obligations	14 800	33 644
Deferred income tax liabilities	65 058	59 503
Total non-current liabilities	784 069	769 196
Trade and other payables	473 523	588 317
Financial liabilities	30 565	30 239
Income tax liabilities	105 453	91 400
Provisions	3 065	4 221
Liabilities included in a disposal group classified as held for sale	110 407	0
Total current liabilities	723 012	714 177
Total liabilities	1 507 081	1 483 373
TOTAL EQUITY AND LIABILITIES	3 478 530	3 321 979

Interim condensed consolidated income statement

(in CHF 1 000)	H1, 2024	H1, 2023 ¹
Revenue	1 273 232	1 143 868
Cost of goods sold	(354 833)	(282 791)
Gross profit	918 399	861 076
Other income	6 379	3 503
Distribution expense	(241 273)	(209 864)
Administrative expense	(347 446)	(342 863)
Operating profit	336 059	311 853
Finance income	88 604	40 384
Finance expense	(94 102)	(72 518)
Share of result of associates	(5 858)	(4 629)
Profit before income tax	324 703	275 090
Income tax	(56 467)	(49 763)
NET PROFIT FROM CONTINUING OPERATIONS	268 236	225 327
Loss from discontinued operations, net of tax	(36 521)	(19 308)
NET PROFIT	231 715	206 019
Attributable to:		
Shareholders of the parent company	230 372	205 776
Non-controlling interests	1 343	243
Earnings per share (EPS):		
Earnings per share for the period attributable to the owners of the parent:		
Basic (in CHF)	1.45	1.29
Diluted (in CHF)	1.44	1.29
Thereof continuing operations:		
Basic (in CHF)	1.67	1.41
Diluted (in CHF)	1.67	1.41

¹ Comparative information for 2023 has been adjusted due to the classification of the direct-to-consumer clear aligner business as discontinued operations.

Interim condensed consolidated statement of comprehensive income

(in CHF 1 000)	H1, 2024	H1, 2023
Net profit	231 715	206 019
Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods:		
Net foreign exchange result on net investment loans	11 257	(841)
Share of other comprehensive loss of associates accounted for using the equity method	(18)	(16)
Exchange differences on translation of foreign operations	15 160	(14 229)
Income tax effect	(1 525)	121
Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	24 874	(14 965)
Other comprehensive income/(loss) not to be reclassified to profit or loss in subsequent periods:		
Change in fair value of financial instruments designated through other comprehensive income	627	2 865
Remeasurements of retirement benefit obligations	19 527	(9 535)
Income tax effect	(2 231)	676
Other comprehensive income/(loss) not to be reclassified to profit or loss in subsequent periods	17 922	(5 994)
Other comprehensive income/(loss), net of tax	42 796	(20 959)
TOTAL COMPREHENSIVE INCOME, NET OF TAX	274 511	185 060
Attributable to:		
Shareholders of the parent company	273 106	184 854
Non-controlling interests	1 405	207

Interim condensed consolidated cash flow statement

(in CHF 1 000)	H1, 2024	H1, 2023 ¹
Net profit from continuing operations	268 236	225 327
Adjustments for:		
Income tax	56 467	49 763
Net interest result	9 796	6 434
Financial impairment result	0	8
Share of result of associates	5 858	4 629
Share-based payments expense	10 851	8 391
Other non-cash items	3 861	14 652
Depreciation and amortization	70 391	59 172
Impairment	0	6 329
Change in provisions, retirement benefit obligations and other liabilities	258	(3 181)
Change in long-term assets	29	(3 544)
Working capital adjustments:		
Change in inventories	(26 588)	(55 916)
Change in trade and other receivables	(99 165)	(47 234)
Change in trade and other payables	(16 053)	25 685
Interest paid on lease liabilities	(4 150)	(3 729)
Interest paid	(3 211)	(2 205)
Interest received	2 347	3 075
Income tax paid	(50 323)	(60 595)
Cash flows from operating activities from continuing operations	228 605	227 062
Cash flows from operating activities from discontinued operations	(25 924)	(30 510)
Cash flows from operating activities	202 680	196 552

¹ Comparative information for 2023 has been adjusted due to the classification of the direct-to-consumer clear aligner business as discontinued operations.

Interim condensed consolidated cash flow statement

(in CHF 1 000)	H1, 2024	H1, 2023 ¹
Purchase of financial assets	(28 935)	(61)
Proceeds from sale of financial assets	67	18 667
Purchase of property, plant and equipment	(60 331)	(69 781)
Purchase of intangible assets	(23 686)	(16 526)
Purchase of investments in associates	0	(6 647)
Disposal of investments associates	9 840	1 736
Acquisition of a business, net of cash acquired	(8 391)	(31 822)
Contingent consideration paid	(6 236)	(21 750)
Proceeds from loans	610	3
Disbursement of loans	(599)	(124)
Dividends received from associates	188	0
Net proceeds from sale of non-current assets	676	1 990
Cash flows from investing activities from continuing operations	(116 796)	(124 314)
Cash flows from investing activities from discontinued operations	(42)	(116)
Cash flows from investing activities	(116 838)	(124 429)
Repayment of non-current financial debts	(1 163)	(1 108)
Increase in non-current financial debts	9 057	8 728
Repayment of current financial debts	(213)	(8)
Dividends paid to the equity holders of the parent	(135 428)	(127 445)
Dividends paid to non-controlling interests	(449)	(198)
Payment of lease liabilities	(13 900)	(12 601)
Sale of treasury shares	10 240	0
Purchase of treasury shares	(27 077)	(25 655)
Cash flows from financing activities from continuing operations	(158 932)	(158 288)
Cash flows from financing activities from discontinued operations	(1 137)	(1 194)
Cash flows from financing activities	(160 069)	(159 482)
Exchange rate differences on cash held	4 321	(5 619)
Less cash and cash equivalents from discontinued operations	(6 738)	0
Net change in cash and cash equivalents	(76 644)	(92 979)
Cash and cash equivalents at 1 January	410 310	696 103
CASH AND CASH EQUIVALENTS AT 30 JUNE	333 666	603 125

¹ Comparative information for 2023 has been adjusted due to the classification of the direct-to-consumer clear aligner business as discontinued operations.

Interim condensed consolidated statement of changes in equity

H1, 2024 (in CHF 1 000)	Attributable to the shareholders of the parent company						Non-controlling interests	Total equity
	Share capital	Share premium	Treasury shares	Translation reserves	Retained earnings	Total		
At 1 January 2024	1 595	102 012	(1 357)	(578 879)	2 312 808	1 836 179	2 427	1 838 606
Net profit					230 372	230 372	1 343	231 715
Other comprehensive income				26 354	16 379	42 733	63	42 796
Total comprehensive income	0	0	0	26 354	246 752	273 106	1 405	274 511
Dividends to equity holders of the parent		(63 731)			(71 697)	(135 428)		(135 428)
Dividends to non-controlling interests						0	(449)	(449)
Share-based payment transactions					11 354	11 354		11 354
Purchase of treasury shares			(27 077)			(27 077)		(27 077)
Usage of treasury shares			27 636		(17 395)	10 240		10 240
Changes in non-controlling interests					93	93	(121)	(28)
Put options to non-controlling interests					(340)	(340)	59	(281)
AT 30 JUNE 2024	1 595	38 282	(798)	(552 525)	2 481 574	1 968 128	3 320	1 971 448

H1, 2023 (in CHF 1 000)	Attributable to the shareholders of the parent company						Non-controlling interests	Total equity
	Share capital	Share premium	Treasury shares	Translation reserves	Retained earnings	Total		
At 1 January 2023	1 595	102 012	(11 080)	(464 107)	2 223 178	1 851 598	2 247	1 853 845
Net profit					205 776	205 776	243	206 019
Other comprehensive loss				(15 033)	(5 889)	(20 922)	(37)	(20 959)
Total comprehensive income/(loss)	0	0	0	(15 033)	199 887	184 854	207	185 060
Dividends to equity holders of the parent					(127 445)	(127 445)		(127 445)
Dividends to non-controlling interests						0	(198)	(198)
Share-based payment transactions					10 672	10 672		10 672
Purchase of treasury shares			(25 655)			(25 655)		(25 655)
Usage of treasury shares			22 807		(22 807)	0		0
Put options to non-controlling interests					(5)	(5)	(97)	(103)
AT 30 JUNE 2023	1 595	102 012	(13 929)	(479 140)	2 283 481	1 894 018	2 158	1 896 176

Notes to the interim condensed consolidated financial statements

1 CORPORATE INFORMATION

Straumann Holding AG is a public company incorporated and domiciled in Switzerland, whose shares are publicly traded on the SIX Swiss Exchange. The unaudited interim condensed consolidated financial statements of the Straumann Group for the six months ending 30 June 2024 were authorized for issue in accordance with a resolution of the Board of Directors on 13 August 2024.

2 BASIS OF PREPARATION AND ACCOUNTING POLICIES

BASIS OF PREPARATION

The interim condensed consolidated financial statements for the six months ending 30 June 2024 have been prepared in accordance with IAS 34 'Interim Financial Reporting'. They provide an update of previously reported information and should be read in conjunction with the Group's annual financial statements as at 31 December 2023. All values disclosed are rounded to the nearest thousand except where otherwise indicated.

The preparation of consolidated financial statements under IFRS requires Management to make estimates and assumptions that affect the reported amounts. Because of the inherent uncertainties, actual outcomes and results may differ from these estimates and assumptions.

CHANGES TO THE GROUP'S ACCOUNTING POLICIES

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group's annual financial statements for the year ended 31 December 2023, except for the adoption of new standards and amendments to existing standards effective as of 1 January 2024. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective. Several amendments apply for the first time in 2024, but do not have a material impact on the interim condensed consolidated financial statements of the Group.

DISCONTINUED OPERATIONS

Non-current assets are classified as assets held for sale or related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell with any resulting impairment recognized. Assets related to discontinued operations and assets of disposal group held for sale are not depreciated or amortized. The prior-year consolidated balance sheet is not restated.

3 DISAGGREGATED REVENUE FROM CONTRACTS WITH CUSTOMERS

The Group derives revenue from contracts with customers in the geographical regions, disclosed in Note 4.

4 SEGMENT INFORMATION

Operating segments for reporting purposes are determined based on the Group's management approach. The external segment reporting aligns with the internal organizational and management structure used within the Group and the financial reporting to the chief operating decision maker (CODM), identified as the Executive Management Board (EMB). The EMB is responsible for the Group's operational management, following the guidance of the Board of Directors. Additionally, it oversees global strategy and stakeholder management.

The reporting segments are presented consistently with the internal reporting to the CODM. The centralized headquarter support functions (e.g. finance, information technology, human resources) and business units such as 'Customer Solutions & Education' and 'Research & Development' are not considered operating segments, as they do not generate separate revenues. Instead, these functions are grouped under the column 'Not allocated items'.

The direct-to-consumer clear aligner business ("DTC Business") was previously included in the "Sales EMEA" operating segment. Due to the intent to sell this business, it is now classified as discontinued operations and is no longer monitored as part of the "Sales EMEA" segment as of the balance sheet date. Consequently, the DTC Business has been removed from this segment, and comparative segment information has been retrospectively adjusted accordingly.

SALES EUROPE, MIDDLE EAST AND AFRICA

'Sales EMEA' comprises the Group's own distribution businesses in the EMEA region, as well as the business with EMEA distributors. The segment also includes the production facility of Medentika in Germany, which manufactures implants and prosthetic components, the implant-supported prosthetics business of Createch and the production facilities of Anthogyr, a French company that develops and manufactures dental implant systems and CAD/CAM solutions. It comprises segment-related management functions inside and outside Switzerland.

SALES NORTH AMERICA

'Sales NAM' comprises the Group's own distribution businesses in the United States and Canada. It also includes the development and production activities of ClearCorrect in the USA and US-based Bay Materials, a company specializing in the design, development and supply of high-performance thermoplastics for orthodontic applications. The segment also includes the development and production activities of Dental Wing in Canada. It comprises segment-related management functions within and outside Switzerland.

SALES ASIA PACIFIC

'Sales APAC' comprises the Group's own distribution businesses in the Asia Pacific region, as well as the business with Asian distributors. It includes AlliedStar, a manufacturer of intraoral scanners (IOS) in China, the business of T-Plus, a Taiwanese company that develops and manufactures dental implant systems and has distribution channels in Taiwan and China, and Nihon, a Japanese provider of implant referrals. It comprises segment-related management functions inside and outside Switzerland.

SALES LATIN AMERICA

'Sales LATAM' comprises the Group's own distribution businesses in Middle and South America as well as the business with Latin American distributors. It includes the production sites of Neodent in Brazil (which manufactures implants, biomaterials, CAD/CAM products and clear aligners) and Yller Biomaterials, a Brazilian company specializing in the development and manufacture of high-tech materials for 3D printing. It comprises segment-related management functions in Switzerland and abroad.

OPERATIONS

'Operations' acts as the principal towards all distribution businesses of the Group. It comprises the main production facilities for implant components and instruments in Switzerland, France and the United States, the CAD/CAM milling centers in Germany, Japan and the United States, the production facility in Sweden for biomaterials and sterile-packaged products and GalvoSurge Dental, a Swiss company specializing in state-of-the-art solutions for dental implants and care. The segment also includes all of the company's logistics functions. It does not include the production facilities of Neodent, Medentika, ClearCorrect, AlliedStar, Dental Wings, Createch, T-Plus, Anthogyr, Bay Materials and Yller Biomaterials.

INFORMATION ABOUT PROFIT OR LOSS AND ASSETS

The following tables present revenue and profit information regarding the Group's operating segments for the six months ended 30 June 2024 and 30 June 2023, respectively.

H1, 2024

(in CHF 1 000)

	Sales EMEA	Sales NAM	Sales APAC	Sales LATAM	Operations	Not Allocated Items	Eliminations	Group
Revenue third party	515 468	364 667	284 750	108 347	0	0	0	1 273 232
Revenue inter-segment	65 139	40 202	102	35 691	726 698	0	(867 832)	0
Total revenue	580 607	404 869	284 852	144 038	726 698	0	(867 832)	1 273 232
Operating profit	68 176	15 368	(6 561)	24 506	458 051	(145 555)	(77 926)	336 059
Financial result								(5 498)
Share of result of associates								(5 858)
Income tax								(56 467)
NET PROFIT FROM CONTINUING OPERATIONS								268 236
Loss from discontinued operations, net of tax								(36 521)
NET PROFIT								231 715

H1, 2023¹

(in CHF 1 000)

	Sales EMEA	Sales NAM	Sales APAC	Sales LATAM	Operations	Not Allocated Items	Eliminations	Group
Revenue third party	486 390	361 964	195 335	100 179	0	0	0	1 143 868
Revenue inter-segment	62 574	35 816	45	27 339	671 567	0	(797 341)	0
Total revenue from continuing operations	548 964	397 780	195 380	127 518	671 567	0	(797 341)	1 143 868
Operating profit from continuing operations	56 245	9 778	(6 009)	11 666	437 539	(112 956)	(84 410)	311 853
Financial result								(32 134)
Share of result of associates								(4 629)
Income tax								(49 763)
NET PROFIT FROM CONTINUING OPERATIONS								225 327
Loss from discontinued operations, net of tax								(19 308)
NET PROFIT								206 019

¹ Comparative information for 2023 has been adjusted due to the classification of the direct-to-consumer clear aligner business as discontinued operations.

The following tables present the segment assets of the Group's operating segments as of 30 June 2024 and 31 December 2023:

at 30 Jun 2024

(in CHF 1 000)

	Sales EMEA	Sales NAM	Sales APAC	Sales LATAM	Operations	Not Allocated Items	Eliminations	Group
Segment assets	728 575	446 542	601 256	523 570	685 919	224 168	(572 209)	2 637 821
Segment assets from discontinued operations	175 072							175 072
Unallocated assets								665 637
Group								3 478 530

at 31 Dec 2023

(in CHF 1 000)

	Sales EMEA	Sales NAM	Sales APAC	Sales LATAM	Operations	Not Allocated Items	Eliminations	Group
Segment assets	838 502	421 044	554 334	514 642	578 561	179 172	(473 136)	2 613 119
Unallocated assets								708 860
Group								3 321 979

SEASONALITY OF OPERATIONS

The Group operates in industries where significant seasonal or cyclical variations in total sales do not occur during the financial year.

5 BUSINESS COMBINATION

SCHMIDT DENTAL

On 3 January 2024, the Group acquired 100% ownership of Schmidt Dental, a Polish distributor of both Group brand and third-party dental products. Following the acquisition, the company was renamed Straumann Polska Sp. z.o.o.

The fair values of the identifiable assets and liabilities as of the date of the business combination are as follows:

(in CHF 1 000)	Fair value
Property, plant and equipment	56
Right-of-use assets	44
Customer relationships	9 515
Inventories	3 529
Trade and other receivables	3 104
Cash and cash equivalents	254
Total assets	16 502
Financial liabilities	100
Deferred income tax liabilities	1 857
Trade and other payables	5 968
Total liabilities	7 925
TOTAL IDENTIFIABLE NET ASSETS AT FAIR VALUE	8 578
Goodwill	14 153
Consideration	22 730
Satisfied in cash	8 645
Contingent consideration	14 085
Consideration	22 730
Cash flow	
Net cash acquired	254
Cash paid	(8 645)
NET CASH OUTFLOW	(8 391)

At the date of the business combination, the fair value of trade receivables amounted to CHF 2.5 million. The fair values did not materially differ from the contractual gross amounts. Contingent consideration payments are based on the performance of the acquired businesses. As of the balance sheet date, 30 June 2024, the fair value of these financial liabilities collectively amounted to CHF 15.0 million.

Goodwill, which is not deductible for tax purposes, includes intangible assets that are not separable, such as expected synergy effects and employee know-how.

In the first six months of the year, the Group's revenues and net profit were not materially impacted by the business combination.

6 DISCONTINUED OPERATIONS

On 20 June 2024, the Group initiated formal proceedings to sell the DrSmile-branded doctor-led direct-to-consumer clear aligner distribution business ("DTC Business"), culminating in the signing of a definitive sale and purchasing agreement (subject to customary regulatory clearance) with Zandivio plc (Impress Group) on 13 August 2024. Founded in 2019, Impress Group is a leading provider for clear aligners in Europe and operates a network of clinics with a focus on Spain, the UK, Italy and Portugal. The decision to complete the sale was approved by the Board of Directors, leading the Group to classify the DTC Business as a disposal group held for sale.

The total net assets to be transferred to Impress Group are expected to amount to approximately CHF 95 million. In return, the Group will receive a 20% non-controlling stake (on a fully diluted basis) in Impress Group. The Group will maintain involvement in Impress Group, particularly as a major supplier of aligners.

The table below provides details of the income statement for discontinued operations:

(in CHF 1 000)	H1, 2024	H1, 2023
Revenue from discontinued operations	45 084	73 020
Expenses	(81 737)	(92 617)
Operating loss from discontinued operations	(36 654)	(19 597)
Income tax	133	289
Net loss from discontinued operations	(36 521)	(19 308)

As of 30 June 2024, the disposal Group DTC Business was recognized at the lower of its carrying amount and fair value less cost to sell, and comprising the following main categories of assets and liabilities:

ASSETS DIRECTLY ASSOCIATED WITH DISPOSAL GROUP

(in CHF 1 000)	30 Jun 2024
Property, plant and equipment	3 005
Right-of-use assets	4 610
Intangible assets	62 100
Financial assets	26
Other receivables	112
Deferred income tax assets	1 324
Total non-current assets	71 177
Inventories	1 008
Trade and other receivables	96 149
Cash and cash equivalents	6 738
Total current assets	103 894
TOTAL ASSETS HELD FOR SALE	175 072

LIABILITIES DIRECTLY ASSOCIATED WITH DISPOSAL GROUP

(in CHF 1 000)	30 Jun 2024
Other liabilities	159
Income tax liabilities	236
Financial liabilities	3 311
Provisions	22
Total non-current liabilities	3 727
Trade and other payables	104 991
Financial liabilities	1 464
Provisions	224
Total current liabilities	106 679
TOTAL LIABILITIES HELD FOR SALE	110 407

7 EARNINGS PER SHARE

BASIC EARNINGS PER SHARE

Basic earnings per share are calculated by dividing the net profit for the period attributable to ordinary shareholders of Straumann Holding AG by the weighted average number of ordinary shares outstanding during the year, excluding ordinary shares purchased by the Group and held as treasury shares.

	H1, 2024	H1, 2023 ¹
Net profit attributable to shareholders (in CHF 1 000)	230 372	205 776
Net profit attributable to shareholders - continuing operations (in CHF 1 000)	266 894	225 084
Weighted average number of ordinary shares outstanding	159 402 012	159 364 389
BASIC EARNINGS PER SHARE (IN CHF)	1.45	1.29
BASIC EARNINGS PER SHARE - CONTINUING OPERATIONS (IN CHF)	1.67	1.41

¹ Comparative information for 2023 has been adjusted due to the classification of the direct-to-consumer clear aligner business as discontinued operations.

DILUTED EARNINGS PER SHARE

Diluted earnings per share are calculated by dividing the net profit for the period attributable to ordinary shareholders of Straumann Holding AG by the weighted average number of ordinary shares outstanding during the year, plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential of outstanding equity instruments into ordinary shares. The number of shares calculated as above is compared with the number of shares that would have been issued assuming the exercise of the Performance Share Units.

	H1, 2024	H1, 2023 ¹
Net profit attributable to shareholders (in CHF 1 000)	230 372	205 776
Net profit attributable to shareholders - continuing operations (in CHF 1 000)	266 894	225 084
Weighted average number of ordinary shares outstanding	159 402 012	159 364 389
Adjustments for instruments issued	44 421	262 995
Weighted average number of ordinary shares for diluted earnings per share	159 446 433	159 627 384
DILUTED EARNINGS PER SHARE (IN CHF)	1.44	1.29
DILUTED EARNINGS PER SHARE - CONTINUING OPERATIONS (IN CHF)	1.67	1.41

¹ Comparative information for 2023 has been adjusted due to the classification of the direct-to-consumer clear aligner business as discontinued operations.

8 PROPERTY, PLANT AND EQUIPMENT & INTANGIBLE ASSETS

During the six months ended 30 June 2024, the Group acquired property, plant, and equipment at a cost of CHF 60.3 million (H1 2023: CHF 69.8 million) and invested in intangible assets amounting to CHF 23.7 million (H1 2023: CHF 16.5 million), excluding assets acquired through business combinations.

9 EQUITY

DIVIDENDS PAID

On 18 April 2024, Straumann Holding AG paid a dividend of CHF 0.85 per share (2023: CHF 0.80) to its shareholders. The total gross dividend paid amounted to CHF 135.4 million (2023: CHF 127.4 million).

10 FINANCIAL INSTRUMENTS

FAIR VALUES

The carrying amounts of cash and cash equivalents, trade and other receivables, and trade and other payables with remaining terms of up to twelve months, along with other current financial assets and liabilities, reasonably approximate their fair values due to the short-term maturities of these instruments.

The cash and cash equivalents classified under Level 1 hierarchy pertain to an investment in a money market fund intended to meet short-term cash commitments. The fund is listed on the SIX Swiss Exchange, and its fair value is derived from quoted market prices.

For domestic bonds listed on the SIX Swiss Exchange, the fair value is determined based on quoted market prices.

The fair value of the put options granted to non-controlling interests is associated with the business combination of Abutment Direct Inc. in 2019.

The fair value of derivatives is determined using market-observed input factors, either directly or indirectly. For foreign exchange forward contracts and non-deliverable forwards, this is based on forward exchange rates. In the first half of 2024, the Group entered into financial derivatives to manage risks related to a component of the deferred consideration for the AlliedStar business combination. The fair value of these derivatives is influenced by the share price performance of Straumann Holding AG.

The unquoted equity instruments classified under Level 3 of the hierarchy primarily include investments in an Irish-based biomaterials development and manufacturing company, a non-listed US consumer health company in the dental sector, and investment funds focused on dental-related opportunities in China and the US. Given that these investments are not actively traded or lack a market, their fair value is determined based on the best available information, such as the net asset value reports of the instruments.

Other financial liabilities classified under Level 3 mainly consist of contingent considerations related to the business combinations of AlliedStar in China, GalvoSurge in Switzerland, the Baltic and Polish Distributors, Digital Planning Service Private Limited in Pakistan, and the investment in Smilecloud in Romania. The fair value of these contingent considerations is determined based on various factors, including profitability targets (for AlliedStar, Baltic and Polish Distributors, GalvoSurge, and Smilecloud), company and product-related milestone achievements (for AlliedStar, GalvoSurge, Digital Planning Service, and Smilecloud), and the share price of Straumann Holding AG shares (for AlliedStar).

The fair value of investments in Level 3 is reviewed regularly for a possible diminution in value.

Fair value hierarchy

The Group uses the following hierarchy for disclosure of the fair values of financial instruments by valuation technique:

- Level 1: Quoted (unadjusted) prices in active markets for identical assets or liabilities
- Level 2: Techniques for which all inputs that have a significant effect on the recorded fair value are observable, either directly or indirectly
- Level 3: Techniques that predominantly use unobservable input data and which are not based on observable market data

As of 30 June 2024 and 31 December 2023, the Group held the following financial instruments:

(in CHF 1 000)

	30 Jun 2024					Fair value
	Amortized cost	Carrying amount (by measurement basis)			Total carrying amount	
		Level 1	Level 2	Level 3		
Financial assets						
Derivative financial assets			26 461		26 461	
Equity instruments				16 936	16 936	
Loans and other financial receivables	10 912				10 912	
Trade and other receivables	471 399				471 399	
Cash and cash equivalents	266 200	67 467			333 666	
Financial liabilities						
Straight bond	199 966				199 966	197 686
Derivative financial liabilities			1 898		1 898	
Put options to non-controlling interests				5 303	5 303	
Lease liabilities	204 419				204 419	
Other financial liabilities	41 985				41 985	
Trade and other liabilities	386 625			230 718	617 343	

(in CHF 1 000)

	31 Dec 2023					Fair value
	Amortized cost	Carrying amount (by measurement basis)			Total carrying amount	
		Level 1	Level 2	Level 3		
Financial assets						
Derivative financial assets			3 227		3 227	
Equity instruments				15 619	15 619	
Loans and other financial receivables	9 617				9 617	
Trade and other receivables	476 055				476 055	
Cash and cash equivalents	308 585	101 725			410 310	
Financial liabilities						
Straight bond	199 944				199 944	196 600
Derivative financial liabilities			1 120		1 120	
Put options to non-controlling interests				5 022	5 022	
Lease liabilities	212 409				212 409	
Other financial liabilities	31 940				31 940	
Trade and other liabilities	472 747			215 004	687 751	

The changes in carrying values associated with Level 3 financial instruments for the six months ended 30 June 2024 and 30 June 2023, respectively:

(in CHF 1000)	Financial assets	Financial liabilities
As at 1 January 2024	15 619	220 026
Additions	687	16 430
Settlements	0	(7 406)
Remeasurement recognized in profit or loss	0	6 707
Remeasurement recognized in OCI	631	(17)
Remeasurement recognized in equity	0	281
As at 30 June 2024	16 936	236 020

In H1 2024, CHF 15.0 million of additions to Level 3 financial liabilities are attributable to the contingent consideration payable in connection with the business combination involving the Polish Distributor. The remaining amount of CHF 1.4 million pertains to an adjustment to the contingent consideration related to the AlliedStar acquisition in November 2023.

Settlements of Level 3 financial liabilities include contingent consideration payments related to the business combinations of Straumann Romania, Nihon, GalvoSurge and the Baltic Distributor.

(in CHF 1000)	Financial assets	Financial liabilities
As at 1 January 2023	20 952	116 954
Additions	0	20 216
Settlements	0	(33 665)
Remeasurement recognized in profit or loss	0	4 630
Remeasurement recognized in OCI	(861)	147
Remeasurement recognized in equity	0	105
As at 30 June 2023	20 091	108 387

In H1 2023, additions to Level 3 financial liabilities relate to the contingent consideration payable in conjunction with the GalvoSurge business combination and the investment in Smilecloud. Settlement of Level 3 financial liabilities mainly relate to the contingent consideration payment in conjunction with the DrSmile business combination (CHF 30.2 million).

During the six-month period ending 30 June 2024 and 30 June 2023 respectively, there were no transfers between Level 1 and Level 2 fair-value measurements, and no transfers into or out of Level 3 fair-value measurements.

The significant unobservable inputs for material financial instruments within Level 3 of the fair value hierarchy, along with their quantitative sensitivity analysis as of 30 June 2024, are as follows:

Instrument	Valuation technique	Significant unobservable input	Sensitivity of the input to fair value
Contingent Consideration AlliedStar	Present value of the estimated redemption value	Units sold	1 000 base-point increase (decrease) in units sold would result in an increase (decrease) in fair value of CHF 4.6 million, resp. CHF -4.6 million.
		Share price	1 000 base-point increase (decrease) in share price would result in an increase (decrease) in fair value of CHF 3.1 million, resp. CHF -3.1 million.
		Interest rate	100 base-point increase (decrease) in the interest rate would result in a decrease (increase) in fair value of CHF -5.1 million, resp. CHF 5.3 million.
Contingent Consideration GalvoSurge	Present value of the estimated redemption value	Gross profit	1 000 base-point increase (decrease) in gross profit would result in an increase (decrease) in fair value of CHF 3.0 million, resp. CHF -3.0 million.
		Interest rate	100 base-point increase (decrease) in the interest rate would result in a decrease (increase) in fair value of CHF -1.6 million, resp. CHF 1.7 million.

The fair value of the contingent consideration for AlliedStar is influenced by technical and commercial milestone achievements, the share price performance of Straumann Holding AG, and the prevailing interest rate at the balance sheet date. For commercial milestone achievements, the expected redemption value primarily depends on the number of scanners sold. For cash payments tied to the share price of Straumann Holding AG, the fair value is affected by its share performance. As of 30 June 2024, the assessed expected achievements result in a fair value of the contingent consideration of CHF 158.0 million (31 December 2023: CHF 151.7 million).

The fair value of the contingent consideration for GalvoSurge primarily depends on the achievement of commercial and technical milestones, which are largely sensitive to the gross profit of GalvoSurge products and the prevailing interest rate at the balance sheet date. Based on the assessed expected achievements, the fair value of the contingent consideration is CHF 32.1 million as of 30 June 2024 (31 December 2023: CHF 33.8 million).

The Group did not provide additional sensitivity analysis for the remaining Level 3 financial instruments as of 30 June 2024, because their quantitative sensitivity is not material to the Group.

11 EVENTS AFTER THE BALANCE SHEET DATE

MININAVIDENT AG (Mininavident)

On 8 July 2024, the Group gained control over Mininavident, by increasing its stake from 39.12% to 96.39%. Mininavident is a technology provider for guided surgery. The total cash consideration amounted to CHF 12.4 million.

The financial effects of this transaction are not recognized at 30 June 2024. The revaluation result on the current investment, the operating results, assets and liabilities of the acquired company will be considered as of 8 July 2024. On the date the Group obtained control over Mininavident, the Group's share of identifiable net assets has not yet been elaborated. Details of the assets taken over and the liabilities assumed, the future revenue and profit contribution of Mininavident and the effect on the cash flow for the Group are not disclosed, as the accounting for the transaction is still incomplete at the time these consolidated financial statements have been authorized for issue.

END OF DOCUMENT